Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr. Thompson on Exciting Advancements in the Field of Multiple Myeloma

December 5th 2016

Michael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses some of the recent exciting advancements in the field of multiple myeloma during the American Society of Hematology (ASH) Annual Meeting.

Anti-BCMA CAR T-Cell Therapy Approaches 80% Response in Myeloma

December 2nd 2016

An investigational anti-BCMA chimeric antigen receptor T-cell therapy demonstrated an objective response rate of 78% in patients with relapsed/refractory multiple myeloma.

Ixazomib Granted Conditional European Approval for Myeloma

November 28th 2016

The European Commission has granted a conditional approval to ixazomib in combination with lenalidomide and dexamethasone for adult patients with multiple myeloma following at least 1 prior therapy.

Dr. Kumar on Future Treatment Landscape of Multiple Myeloma

November 23rd 2016

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses his vision for the future treatment landscape of multiple myeloma.

Dr. Fonseca on FDA Approval of Daratumumab Triplets in Multiple Myeloma

November 22nd 2016

Rafael Fonseca, MD, professor of Medicine, Mayo Clinic, discuses the recent FDA approval of daratumumab (Darzalex) in combination with lenalidomide and dexamethasone or bortezomib (Velcade) and dexamethasone for patients with relapsed multiple myeloma following at least 1 prior therapy.

FDA Approves Daratumumab Triplets for Relapsed Myeloma

November 22nd 2016

The FDA has approved daratumumab in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for patients with relapsed multiple myeloma following at least 1 prior therapy, based on findings from the phase III POLLUX and CASTOR studies.

Dr. Moreau on Combination Treatments in Multiple Myeloma

November 22nd 2016

Philippe Moreau, MD, head of the Hematology Department, University Hospital of Nantes, France, discusses the combination treatments being used to treat patients with multiple myeloma.

Myeloma Paradigm Shifts With Continued Success of Combo Regimens

November 15th 2016

Pivotal clinical trial findings from the past year will likely have a game-changing effect on the multiple myeloma landscape, according to Rafael Fonseca, MD. Moreover, he adds, oncologists may be looking at a future where the number of drugs in a single regimen continues to grow in an effort to further improve outcomes.

Myeloma Landscape Undergoing Dramatic Shift With Approvals, Pivotal Data

November 11th 2016

Impactful clinical trial data that have led to approvals of novel agents and regimens over the last few years has led to a significant transformation in the multiple myeloma landscape.

Immunotherapy Agents Landing in Myeloma Landscape

November 10th 2016

Using combination regimens in an effective manner will likely be a go-to method with immunotherapy in multiple myeloma, in an effort to induce durable responses in patients.

Dr. Kumar on the Management of Elderly Patients With Multiple Myeloma

November 10th 2016

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the management of elderly patients with multiple myeloma.

Myeloma Advances Result in More Remissions, Better QOL

November 3rd 2016

Sundar Jagannath, MD, discusses the importance of the standardization of a 3-drug regimen for newly diagnosed multiple myeloma, how the regimen may evolve going forward, and other novel agents on the horizon.

Dr. George Somlo on Treatment Considerations for Multiple Myeloma

October 25th 2016

George Somlo, MD, medical oncologist, City of Hope, discusses treatment considerations in multiple myeloma.

Denosumab Delays SREs in Multiple Myeloma

October 22nd 2016

Denosumab is noninferior to zoledronic acid at delaying skeletal-related events for patients with multiple myeloma.

Dr. Fonseca on Pivotal Trials in Multiple Myeloma

October 20th 2016

Rafael Fonseca, MD, professor of Medicine, Mayo Clinic, discusses some of the ongoing clinical trials that could be potentially practice changing for the treatment of patients with multiple myeloma.

Dr. Shaji Kumar on New Criteria for Response and MRD Assessment in Multiple Myeloma

October 19th 2016

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the International Myeloma Working Group’s recently released updated consensus criteria for response and minimal residual disease (MRD) assessment in multiple myeloma.

Dr. Somlo on Novel Agents in Multiple Myeloma

October 18th 2016

George Somlo, MD, medical oncologist, City of Hope, discusses some of the novel agents being evaluated for the treatment of patients with multiple myeloma.

Dr. Jagannath on Role for Two-Drug Combinations, Carfilzomib Triplet in Multiple Myeloma

October 14th 2016

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of Medicine (Hematology and Medical Oncology) at the Tisch Cancer Institute, Mount Sinai Cancer Center, discusses induction therapy for multiple myeloma.

Dr. Sonneveld on Incorporating Genomic Profiling Into Myeloma Management

October 13th 2016

Pieter Sonneveld, MD, PhD, head of the Department of Hematology, Erasmus University Medical Center, discusses how the incorporation of genomic profiling will play into the overall management of patients with multiple myeloma.

Dr. Shaji Kumar on MRD in Multiple Myeloma

October 11th 2016

Shaji Kumar, MD, professor of Medicine at Mayo Clinic, discusses how minimal residual disease (MRD) testing has evolved in multiple myeloma.